



Turning Precision Medicine Into Action

When you're driven to improve cancer patients' lives, turn to a leader in oncology clinical trial development. **CerbACT Asia** empowers Precision Medicine Research by applying deep and wide biomarker expertise, translational research, and clinical development strategy.

We are dedicated to provide services to our clients at the highest quality standards, and we welcome you to join us in pushing the forefront of precision medicine for those patients in need.



Services

Cutting-edge Flow Cytometry Services:

CerbACT Asia has completed CAP proficiency tests on immune-phenotyping using TBNK IVD panel (Cat. # 644611) with FACSLytic flow cytometer system from BD Biosciences.

Exploratory flow panel can be customized and validated.

In Vitro Diagnostic Histopathology Services:

CerbACT Asia has completed CAP proficiency tests on:

- CerbACT Asia has completed CAP proficiency tests on CD20 staining using L26 primary antibody (Cat. # 05267099001), using the BenchMark Ultra IHC system from Ventana/Roche Diagnostics. Exploratory IHC panel can be customized and/or validated.

Exploratory IHC panel can be customized and/or validated.



Turnaround time

Flow Cytometry:

- 5 working days for TBNK IVD panel

Immunohistochemistry:

- 10 working days for CD20 panel



Hours of operation

Monday to Friday, 09:30 - 17:30 (GMT +8)



Contact information

Allen Kuo, PhD

BD Director, CerbAct Asia

akuo@cerbactasia.com